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OBJECTIVE: Rapidly dividing cells in multiple types of cancer and inflammatory diseases undergo high low
density lipoprotein (LDL) uptake for membrane synthesis, and coupling an LDL-like nanoemulsion, containing
lipid nanoparticles (LDE) to a chemotherapeutic agent efficiently targets these cells without significant systemic
effects. This was a prospective exploratory study that evaluated the uptake of a radioactively labeled LDE
emulsion by receptors of endometriotic foci and the capacity of the LDE for cellular internalization.
METHODS: The lipid profile of each patient was determined before surgery, and labeled LDE were injected into
fourteen patients with intestinal or nonintestinal endometriosis. The radioactivity of each tissue sample
(intestinal endometriosis, nonintestinal endometriosis, healthy peritoneum, or topical endometrium) was
measured.
RESULTS: The group with intestinal endometriosis presented higher levels of plasma LDL but lower LDE uptake
by foci than the nonintestinal group, suggesting less cell division and more fibrosis. The uptake of LDE was
highest in the topical endometrium, followed by the healthy peritoneum, and lowest in the endometriotic
lesion. Since the endometriotic foci showed significant LDE uptake, there was likely increased consumption of
LDL by these cells, similar to cells in cancers and inflammatory diseases. Plasma cholesterol levels had no
influence on LDE uptake, which showed that the direct delivery of the nanoemulsion to target tissues was
independent of serum lipoproteins. There were no significant differences in the parameters (p40.01) because
of the small sample size, but the findings were similar to those of previous studies.
CONCLUSION: Nanotechnology is a promising therapeutic option for surgery and hormonal blockage for deep
endometriosis, with a lower complication rate and no systemic side effects.
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’ INTRODUCTION
Endometriosis is a frequent gynecological disease that
affects approximately 10% of women of reproductive age.
This disease represents a considerable therapeutic challenge,
especially with respect to deep endometriosis, in which
lesion infiltration can exceed 5 mm; deep endometriosis
occurs in up to 12% of patients (1-6).
The clinical treatment of deep endometriosis, an estrogen-
dependent disease, is based on hormonal suppression.
However, the results of this treatment are unsatisfactory
since burdensome side effects that include climacteric symp-
toms, decreased bone mineral density, and irregular men-
strual cycles are frequent; treatment is not effective in
reducing endometriotic nodules, and symptoms often recur
after treatment withdrawal (7-9).
The surgical approach is thus considered the gold standard
for the treatment of deep endometriosis, but surgical com-
plications, such as fistulas, hemorrhage, infection, intestinal
subocclusion, bladder dysfunction or intestinal dysfunction,
may be hazardous and even life threatening. Moreover, the
effectiveness of surgery is also limited, with lesion recurrence
rates of up to 20% and frequent postsurgical persistence of
endometriotic foci (6,10-15). In this setting, new strategies for
the treatment of deep endometriosis are mandatory, but the
several therapeutic alternatives proposed to date have been
proven to be ineffective or have not yet been tested in women
(9,16-18).
Endometriosis is basically a proliferative and inflamma-
tory disease. In rapidly proliferating tissues, acceleratedDOI: 10.6061/clinics/2019/e989
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mitosis requires high amounts of cholesterol to build new cell
membranes. Thus, overexpression of low density lipoprotein
(LDL) receptors occurs to take up LDL cholesterol into cells
to meet rising cholesterol demands (19). The strong avidity
of these cells for cholesterol allows the use of LDL for the
purpose of effectively targeting chemotherapeutic drugs to
proliferating tissues such as cancer and inflammatory tissues.
In pioneering studies, Maranhao et al. (20) showed that
artificially made nanoparticles, termed lipid nanoparticles
(LDE) and which resemble the structure of the native LDL,
also have the ability to carry chemotherapeutic agents to
target tissues, such as neoplastic, atherosclerotic or inflam-
matory tissues (20-29).
Recently, we showed that in fragments of deep endome-
triotic tissues excised from patients during surgery, LDL
receptors were overexpressed. These results suggested that
LDL uptake and, conceivably, LDE uptake by these tissues
could be increased. Thus, this study aimed to investi-
gate whether LDE are taken up by endometriotic tissues
in women, which could lay the foundation for the use of
an LDE drug carrier system as a new strategy to treat deep
endometriosis.
’ METHODS
The present pilot study was performed at the Gynecolo-
gical Clinic at Hospital das Clínicas of the University of Sao
Paulo Medical School (HC-FMUSP), where 14 patients were
divided into two groups: one group comprised patients
with intestinal endometriosis, and the other group com-
prised patients with deep endometriosis at other pelvic sites
(nonintestinal endometriosis group).
The inclusion criteria were as follows: aged between
18 and 45 years; histologically proven ovarian or deep
endometriosis; eumenorrheic menstrual cycles; and no use
of hormone therapy, including gonadotropin-releasing
hormone (GnRH) analogs, progestogens, and hormonal con-
traceptives, for three months prior to surgery.
All patients were clinically evaluated, and the indication
criteria for surgical treatment of endometriosis were suspi-
cion of obstructive ureteral or intestinal involvement (terminal
ileus, appendix, or rectosigmoid with signs of subocclusion),
ovarian endometriomas above 6.0 cm, or patients with-
out clinical improvement (of pelvic pain) after 12 months of
clinical hormonal treatment.
Prior to surgical intervention, the lipid profile of each
patient in both groups was determined from serum samples
obtained after a 12-hour fast. On the day prior to surgery,
0.1 ml of solid cholesterol lipid core nanoparticles (i.e., LDE)
with cholesterol [14C]-oleate was injected intravenously into
each patient in both groups.
On the day of surgery, a topical endometrial sample was
collected using a Pipelle curette. Patients were subjected to
videolaparoscopy for diagnostic confirmation of endome-
triosis, resection of lesions was performed, and a sample of
healthy peritoneal tissue adjacent to one of the lesions of
endometriosis was also obtained. The sites of the lesions
were divided into ovary, retrocervical region, vagina, bladder,
and rectosigmoid. Then, subjects were classified into intestinal
and nonintestinal groups.
After the proposed surgical procedure, the pathologist
and the surgeon, who followed all the procedures, selected
samples of endometriotic tissues and healthy peritoneal
tissues via macroscopic analysis of the surgical specimen.
This same pathologist performed the endometrial timing to
confirm the phase of the cycle of the patient. The topical
endometrial tissue, the endometriotic foci, and the adjacent
healthy peritoneal fragment were divided into two parts and
separately sent for histopathological analysis and radio-
activity analysis.
Triglycerides and cholesterol fractions were measured
with the colorimetric-enzymatic method using commercial
kits (Labtest, Sao Paulo, Brazil) or calculated using the
Friedewald et al. (1972) formulas: LDL=total cholesterol -
(VLDL+HDL) and VLDL=TGL/5.
The LDE were prepared according to the technique modi-
fied by Maranhao et al. (30). Lipids were extracted from tissue
samples collected according to the conventional method
described by Folch et al. (31) and then processed according
to the method reported by Maranhao et al. (32), and radio-
activity was measured with a liquid scintillation spectrometer
(Packard 1600 TR, Palo Alto, CA).
The injected radiological dose was evaluated according to
the standards of the International Commission on Radio-
logical Protection (ICRP) (33).
The Kruskal–Wallis test (34) was used to compare the
patients’ characteristics and the results of the tests. The
amount of the injected emulsion found at sites of interest
standardized for 1 g was determined according to the group
and compared between the groups using the Kruskal–Wallis
test. Friedman’s test or paired Wilcoxon’s test was used to
identify differences between sites for each group (34). The
level of significance was 1% to correct for multiple com-
parisons. Spearman’s correlations (34) were used to compare
laboratory tests to the amount of fluid found at the sites
of interest for the women with endometriosis to validate
whether migration of the substance to these sites was
influenced by laboratory test levels. Only nonparametric
tests were used because of the small number of samples in
each group, and therefore, there was no assumption about
the data evaluated. The tests were performed with a signi-
ficance level of 5%.
Ethical Approval
The institutional review board approved the project
(number: 435.641-10/16/13). The patients were previously
informed about the research content, and all of them signed
informed consent forms prior to the start of the study.
’ RESULTS
The results of 14 patients were evaluated: 6 presented with
intestinal endometriosis (intestinal endometriosis patients,
IEP), and 8 presented with nonintestinal lesions (nonintest-
inal endometriosis patients, NIEP). Within this group,
1 patient had a retrocervical lesion, 1 had an ovarian endo-
metrioma, 4 had retrocervical lesions and ovarian endome-
triomas, and 2 had retrocervical and bladder lesions. The
mean age was slightly higher in the nonintestinal endome-
triosis group (39.6 years) than in the intestinal endometriosis
group (36 years), with no statistically significant difference
(p=0.136), as shown in Table 1. Similarly, no significant
difference was observed in body mass index (BMI) between
the different groups (p=0.730). With regard to the phase of
the menstrual cycle, 3 patients from the intestinal endome-
triosis group and 5 from the nonintestinal group were in the
follicular phase. For two patients, determining the phase of
the cycle was not possible.
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The clinical presentation of endometriosis varied between
groups. The patients with intestinal lesions (the IEP group)
had dysmenorrhea, while 62.5% of the cohort had no bowel
lesions (NIEP group). Deep dyspareunia was reported in
100% and 87.5% of IEPs and NIEPs, respectively, but no
differences were observed between the endometriosis groups
concerning chronic pelvic pain or infertility (66.7% versus
62.5% and 50.0% versus 50.0%, respectively, for the IEP and
NIEP). Cyclic intestinal alteration was reported in 66.7% of
IEP and 25.0% in NIEP. Cyclic urinary alterations were more
common in NIEP than in IEP (50% and 16.7%, respectively).
Table 2 shows the laboratory parameters evaluated in
this study. The nonintestinal endometriosis group showed
a tendency toward having lower total cholesterol, LDL
cholesterol, and triglycerides. No significant differences were
observed between the groups (p40.05).
Table 3 shows the comparison of the LDE uptake level in
the different tissues of both groups (intestinal endometriosis
and nonintestinal endometriosis). In the statistical analysis of
these values, no significant difference in the amount of LDE
uptake was found between the groups (p40.01).
Figure 1 shows the uptake values of the labeled lipid core
nanoparticles (LDE), divided by group (IEP and NIEP) and
uptake according to the site evaluated (peritoneum, endo-
metrium, and endometriosis). Endometrial tissues showed
uptake of the LDE in a similar manner. Although not statis-
tically significant, uptake was highest in the endometrium,
followed by the peritoneum and, finally, the endometriotic
tissue (p40.01).
Spearman’s correlations (34) were calculated between
laboratory tests and the amount of fluid found at sites of
interest to verify whether migration of the substance to these
sites was influenced by the levels in laboratory test results. In
comparisons of the level of nanoparticle uptake at the
different sites evaluated with the results of the laboratory
tests of the patients (Table 4; r value), no statistically
significant difference was found between the parameters
(Table 4; p40.05).
’ DISCUSSION
Surgical treatment of deep endometriosis remains the most
effective therapeutic option. However, technical difficulties
are often encountered, and complications can be serious. The
rates of different complication types vary between studies,
but the most common complications are recurrent lesions
(5.8% to 20%), fistulas (1.8% to 2.6%), hemorrhage (2.0 to
2.5%), infection (0.6% to 0.8%), intestinal subocclusion (0.2
to 2.7%), and bladder and/or intestinal dysfunction (3.6 to
9.8%) (6,10-15). In addition, surgery depends on specialized
teams for cases of greater complexity, demonstrating the
need for other alternatives to control deep endometriotic
nodules, as well as clinical symptomatology.
Table 1 - Clinical parameters are expressed as the mean and standard deviation of the different groups: without endometriosis, with
intestinal endometriosis, and with endometriosis in other sites (nonintestinal).
Variable Group
Control (CG) (n=3) Intestinal (IEP) (n=6) Nonintestinal (NIEP) (n=8) p
Age (years) 30.3±2.9 36±9.4 39.6±5.8 0.136
Weight (kg) 75.1±25 67.8±12.2 74.5±14.7 0.788
Body mass index (kg/m2) 28.8±7.0 27.3±4.2 28.8±3.7 0.730
Kruskal–Wallis test.
Table 2 - Results for total cholesterol concentrations, their fractions and triglyceride levels in mg/dL (average and standard deviation)
of the three groups of patients: no endometriosis, intestinal endometriosis, and endometriosis in other sites (nonintestinal).
Variable (mg/dL) Group
Control group (CG) (n=3) Intestinal (IEP) (n=6) Nonintestinal (NIEP) (n=8) p
Total cholesterol 226±49 198±35 154±53 0.26
HDL cholesterol 45±14 47±3 46±15 0.83
LDL cholesterol 112±26 121±24 87±40 0.21
Triglycerides 115±20 155±59 107±40 0.29
Kruskal–Wallis test; mg/dL, milligrams per deciliter.
Table 3 - Uptake of labeled nanolipid emulsion at the sites of interest (peritoneum, endometriosis and endometrium), expressed as the
mean and standard deviation, according to patient group, namely, no endometriosis, intestinal endometriosis, and endometriosis in
other sites (nonintestinal), and comparative test results.
Variable (cpm/g) Group
Control (n=3) Intestinal (n=6) Nonintestinal (n=8) p*
Peritoneum 665 (739.9) 316.7 (511.9) 712.3 (1069.1) 0.538
Endometriosis – 180.8 (169.8) 197.5 (403.5) 0.651
Endometrium 1152.3 (1332.2) 1340.4 (2220.4) 709.9 (1275.5) 0.941
*Kruskal–Wallis test. Due to the multiple comparisons, the tests were analyzed with a significance level of 1% (a=0.01). Cpm/g (radioactive count/tissue
gram).
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LDL is the largest cholesterol transporter of the body
(35,36), and tumor cells have increased LDL uptake com-
pared to normal cells (32,35,37-40). This phenomenon occurs
due to the increased need for cholesterol by tumor cells for
membrane synthesis in cell growth and division (41). This
is the main motivation for investigating LDL as a specific
transport vehicle for antineoplastic drugs; the transport
vehicle is developed by incorporating alternative molecules
in place of the original molecule and substituting its internal
lipids with other hydrophobic compounds (42) to limit the
side effects of the drug and prevent the development of drug
resistance (43).
Currently, chemotherapeutic agents, such as paclitaxel,
carmustine, and etoposide, are being made to be nearly
devoid of systemic toxicity when carried in an LDE, an
artificial lipid emulsion similar to the LDL that has been
demonstrated in experimental animals and patients with
advanced cancers and atherosclerosis and has shown a good
capacity for cellular destruction (20-22,26-29). LDE make it
possible to use LDL receptor-mediated endocytosis in clinical
practice because, unlike the native LDL, LDE preparations of
drugs stably associated with LDE can be amenable to being
manufactured at an industrial production scale.
Endometriosis may have a pathophysiological correlation
with cancer due to similar mechanisms of growth and
invasion (44) and to higher plasma LDL levels in endome-
triosis patients than in normal controls (45,46), which is also
observed for some types of cancer (39,47). The overexpression
Figure 1 - Uptake values of the labeled lipid nanoparticles (LDE) of each group (control, intestinal endometriosis, and nonintestinal
endometriosis) and of the site evaluated (peritoneum, endometrium, and endometriosis) in each group.
Table 4 - Values of correlations between the levels of nanoparticles found at the sites of interest (peritoneum, endometriosis, and
endometrium), concentrations of total cholesterol and its fractions, and levels of triglyceride in patients with endometriosis.
Correlation Peritoneum Endometriosis Endometrium
TC r 0.321 0.333 0.286
p 0.365 0.347 0.493
n 10 10 8
HDL r 0.201 0.237 0.143
p 0.578 0.510 0.736
n 10 10 8
LDL r 0.261 0.176 0.143
p 0.467 0.627 0.736
n 10 10 8
TGL r -0.261 -0.188 -0.405
p 0.467 0.603 0.320
n 10 10 8
Spearman’s correlation
r=uptake rate with serum parameter; p=p index; n=number of patients.
4
Nanotechnology and endometriosis: LDE uptake
Bedin A et al.
CLINICS 2019;74:e989
of LDL receptors on the cell membranes of endometriotic
lesions, compared to the topical endometrium, suggests the
increased need for LDLs for cell membrane formation in
dividing cells (19), a principle that also applies to cancer.
The present study was a pilot study that aimed to validate
whether these LDL receptors, overexpressed in endometrio-
tic foci, could take up the labeled LDE. The small sample
size, namely, 14 patients, was comparable to those of pre-
vious similar studies (Maranhao et al. (20): 42 patients;
Azevedo et al. (23): 4 patients; Pinheiro et al. (24): 16 patients;
Pires et al. (26): 5 patients; and Graziani et al. (27): 14
patients). The control group comprised the other evaluated
tissues (peritoneum and normal endometrium). The control
group of subjects is necessary in the second stage of a study,
when there would be a drug coupled to the nanoparticle to
treat the disease.
The ‘‘Annual Limit for Intake’’ (ALI) parameter of a
radionuclide is defined as the amount of radioisotope that
induces an equivalent dose of 50 mSv. For organic compo-
nents labeled with 14C, the ALI values are 9 107 Bq (33). In
the present study, the injected dose of 14C was 22.2 104 Bq,
which equals (22.2 104 Bq/9 107 Bq) 50 mSv=0.12233
msV. The equivalent dose incorporated into the whole body
as a consequence of exposure to radioactive lipids is esti-
mated to be 0.04 mSv, as assessed by the Medical Internal
Radiological Dosimetry (MIRD) method (48). This value is
within the mean described in laboratory evaluations of these
parameters in humans (49). The method described above
allowed us to estimate the injected dose of 14C cholesterol
oleate in the participants of this study: 0.26 mGy in the lower
large intestine, 0.5 mGy in the upper large intestine, 0.18
mGy in the skin, 13 mGy on the bone surface, and 0.13 mGy
in the liver. The dose administered to the lungs, heart, and
ovaries was insignificant. The dose-equivalent incorporated
into the whole body, as a consequence of exposure to radio-
active lipids, was estimated to be 0.02 mSv as assessed using
the MIRD method (32). The maximum dose of radioactivity
exposure for the general public (nonoccupational dose),
according to the radiation protection guidelines, is 5 mSv per
year (50). Comparatively, a chest X-ray is equivalent to
0.1 mSv, which is the dose-equivalent incorporated into the
whole body; a full-body computed tomography scan is
equivalent to 11 mSv; and an air travel time of 10 hours is
equivalent to 0.05 mSv. Thus, previous studies were ethically
approved, since nanoparticle biosafety has been demon-
strated in both target and healthy control groups (32,33,
51-53); therefore, the risk of harmful radioactive effects is not
significant.
The comparisons between groups (intestinal and non-
intestinal endometriosis; Table 1) showed no significant
differences in the clinical parameters (p40.01), including age
and menstrual cycle phase, indicating that the groups were
clinically for comparisons. Despite this finding, the group
with intestinal endometriosis presented a lower BMI, com-
parable to the meta-analysis of Zhu et al. (54), where despite
the heterogeneity of the groups analyzed, the presence and
severity of endometriosis were inversely proportional to
BMI. This difference, although not statistically significant
since this was a pilot study with a small sample size, could
also be observed in relation to symptomatology (Table 2):
women in the control group had no symptoms of endome-
triosis, and those in the intestinal endometriosis group
were more symptomatic in terms of pain than those with
nonintestinal endometriosis. Respectively, in the intestinal
and nonintestinal endometriosis groups, 87.5% and 62.5% of
patients had dysmenorrhea, 66.7% and 62.5% of patients
had chronic pelvic pain, and 66.7% and 25.0% of patients
complained of a cyclic intestinal disorder. In contrast, women
with nonintestinal endometriosis had more symptoms of
deep dyspareunia (100% versus 87.5% of those with intestinal
endometriosis) and cyclical urinary changes (50% vs. 16.7%).
These findings support the data from other studies, where
deep endometriosis, with extensive involvement, was observed
to correspond to cases of greater symptomatology (1,55-57).
Regarding the level of cholesterol, which can indirectly
demonstrate a high metabolism status due to inflammation
and a high level of cell division, the group with intestinal
endometriosis presented the highest levels of LDL: 121 mg/
dL (control, 112 mg/dL, and nonintestinal endometriosis,
87 mg/dL, p40.01; Table 3). These results confirm those of
previous studies, which suggest hypercholesterolemia in
women with endometriosis (45,46), and larger groups are
recommended for this evaluation.
In Table 3, LDE uptake in different tissues of each group
was compared. The peritoneum tended to take up more
LDE in women with nonintestinal endometriosis (mean of
712.3 U; p40.1). In lesions of nonintestinal endometriosis,
the mean uptake level was greater than that in lesions of
intestinal endometriosis (p40.1), showing greater LDL
internalization, which suggests fewer fibrotic tissues in these
cases. In the topical endometrium, LDE emulsion uptake
in the intestinal endometriosis group (1340.4 cpm/g) was
higher than that in the nonintestinal endometriosis group
(709.9 cpm/g, p40.1). Despite this result, in the statistical
analysis of these values, no significant difference was
observed in the level of nanoparticle uptake between the
different tissues (p40.01). Moreover, the comparison of LDE
uptake by each site in the evaluation (healthy peritoneum,
endometriotic lesion and topical endometrium) did not show
any statistically significant difference between the groups
(Figure 1), despite the observation of decreasing uptake by the
topical endometrium (1067.5 cpm/g), healthy peritoneum
(564.7 cpm/g), and endometriotic lesion (189.2 cpm/g). Since
this is a pioneering study, no data from the literature are
available with regard to the uptake of the LDE in endo-
metriosis for comparison.
However, the result that endometriotic foci (intestinal or not)
significantly take up LDE suggests increased LDL consumption
in endometriotic lesions, as well as in cancer and inflammatory
diseases, where LDE was tested as drug carriers (20-26).
The results of this study are preliminary but show high
uptake of labeled LDE by the topical endometrium (Tables 4
and 5). One possible interpretation of this result is that the
topical endometrium is a tissue with an increased rate of cell
division, since it proliferates, thickens, and desquamates
cyclically in a short period of time. Such cyclic renewal of all
endometrial tissue also suggests that the eventual uptake of
the drug by the same mechanism would not compromise
endometrial function, since cellular apoptosis would happen
independently of the treatment, and new cells would appear
soon after. Nevertheless, future studies are necessary for this
evaluation, and women with no reproductive aspirations
should be selected first. Further studies should also be
carried out to evaluate other possibilities of treatment side
effects, such as alterations to the ovarian reserve, with a
blocking drug coupled to an LDE.
In the present study, the possibility of labeled LDE uptake
by the tested tissues having an influence on plasma
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cholesterol levels (Table 4) was also evaluated, and no signi-
ficant differences among the different groups/tissues was
found. This confirms the direct delivery of the nanoemulsion
to the tissues with high levels of cell division, independent of
serum lipoproteins.
In conclusion, 14C-labeled LDE were taken up by the endo-
metriotic tissues of patients with ovarian and deep endome-
triosis, by the healthy peritoneum adjacent to the lesions, and
by the endometrium. In the nonintestinal endometriotic
lesions, the mean uptake value was greater than that in the
intestinal endometriosis lesions.
These results can lead to the development of new stu-
dies evaluating nanotechnology as a therapeutic option for
radical surgeries and their complications. In addition, due
to the lack of systemic side effects, when this technology is
compared to systemic hormonal blocks that are currently
available as a therapeutic option, further studies will be
motivated to attempt to develop a more effective treatment
with fewer complications than the treatments that are
currently available or to develop an adjuvant treatment to
lower surgical invasiveness.
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